UPDATE 1-Aclaris Therapeutics to stop development of rheumatoid arthritis drug
In this article:
(Adds details in paragraphs 2 and 3, shares in paragraph 4)
Nov 13 (Reuters) - Aclaris Therapeutics on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial.
There was no notable differentiation between the drug, zunsemetinib, and placebo across any measures of efficacy at 12 weeks, the company said.
The company will also be halting enrollment in an ongoing mid-stage trial studying the drug in psoriatic arthritis.
Shares of the company were halted before the opening bell. (Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)
